Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Down 5.0% Today

What is Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals, Inc. (AMLYX) is a pharmaceutical company that has been experiencing a bearish movement in the stock market today.

Why is Amylyx Pharmaceuticals going down?

AMLX stock is down 5.0% on Oct 17, 2025 14:16

• The strong bearish movement in AMLX stock today could be attributed to profit-taking by investors after a period of solid earnings estimate revision activity.
• Despite belonging to a strong industry, the stock may have faced selling pressure due to market volatility or broader economic concerns.
• Investors might be reassessing their positions in AMLX stock, leading to a temporary decline in its market value.

AMLX Price Chart

AMLX Technical Analysis

AMLX News

Is AMLX Stock a Solid Choice Right Now?

Amylyx has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

https://www.zacks.com/stock/news/2770614/is-amlx-stock-a-solid-choice-right-now

Trending Today

ZCash ($ZEC) Crypto Forecast: Up 17.6% Today

Bitcoin Cash ($BCH) Crypto Forecast: Up 8.2% Today

Solana ($SOL) Crypto Forecast: Up 5.9% Today

Shiba Inu ($SHIB) Crypto Forecast: Up 5.1% Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.7% Today

Floki ($FLOKI) Crypto Forecast: Up 5.0% Today

Chainlink ($LINK) Crypto Forecast: Up 5.1% Today

Cardano ($ADA) Crypto Forecast: Up 5.1% Today

Ethereum ($ETH) Crypto Forecast: Up 5.1% Today

Sonic (prev. FTM) ($S) Crypto Forecast: Up 5.2% Today

Amylyx Pharmaceuticals Price History

17.08.2024 - AMLX Stock was up 10.3%

• Recent executive purchases of shares in Reneo Pharmaceuticals and other stocks priced below $5 could signal optimism towards the pharmaceutical sector, potentially benefiting similar companies like AMLX.
• The market's bullish trend, reflected in the Dow Jones index, likely created a favorable atmosphere for small-cap stocks such as AMLX to perform well.
• The insider buying activity may have been viewed by investors and traders as a show of support for the industry, leading to increased interest in AMLX and driving its positive movement.

27.07.2025 - AMLX Stock was up 5.1%

• AMLX stock surged as investors reacted positively to the company's strategic shift in focus from AMX0035 to avexitide and amyotrophic lateral sclerosis programs.
• The decision to halt the Phase 2b trial for AMX0035 in progressive supranuclear palsy, despite showing no benefit over placebo, was seen as a prudent move by the company to reallocate resources to more promising programs.
• The announcement of a cash runway through 2026 provided investors with confidence in the company's long-term sustainability and growth potential, contributing to the bullish sentiment surrounding AMLX stock today.

25.05.2025 - AMLX Stock was up 9.2%

• AMLX displayed significant bullish movement in the market today.
• The upward trend can be attributed to optimistic analyst views regarding the company's potential PBH treatment, which is estimated to target a $2 billion global market by 2035.
• Investor enthusiasm is likely fueled by the anticipation of Avexitide's Phase 3 trial results in the first half of 2026 and the positive outcomes seen in Phase 2 trials.
• Positive analyst initiations and coverage have also played a role in fostering a favorable outlook on AMLX, signaling increasing confidence in the company's future prospects.

18.10.2024 - AMLX Stock was up 7.1%

• The bullish movement in AMLX could be attributed to positive analyst sentiment and upgrades in the online trading sector, similar to recent developments with other companies in the industry.
• This change in outlook by analysts may have instilled confidence in investors, leading to increased buying activity and driving the stock price higher.
• The overall optimism in the online trading industry, as indicated by the analyst upgrades, likely contributed to the positive momentum seen in AMLX today.

07.04.2025 - AMLX Stock was down 5.7%

• A positive upgrade of Logitech International by a prominent Wall Street analyst possibly drew investor attention away from Amylyx Pharmaceuticals, resulting in a decline in AMLX shares.
• The favorable outlook on Logitech International could have prompted a sector shift, with investors reallocating resources from pharmaceuticals like AMLX to technology-oriented firms.
• The upgrade of Logitech International might have eclipsed any recent developments or announcements concerning Amylyx Pharmaceuticals, contributing to the stock's decline.
• Investors may be adjusting their investment portfolios influenced by changing analyst evaluations, leading to a redirection of focus from AMLX to other companies with more favorable ratings.

14.06.2025 - AMLX Stock was up 5.3%

• AMLX stock surged due to positive results from the Phase 2b trial of their drug avexitide, which showed a significant reduction in hypoglycemic events post-weight loss surgery.
• The promising data from the trial likely boosted investor confidence in the drug's potential success in the market, leading to the bullish movement in AMLX stock.
• The positive news overshadowed other market events such as the drop in PPI and Industrial Production, indicating that investors were primarily focused on the favorable trial results of avexitide.

17.09.2025 - AMLX Stock was down 5.0%

• The strong bearish movement in AMLX stock today could be attributed to profit-taking by investors after a period of solid earnings estimate revision activity.
• Despite belonging to a strong industry, the stock may have faced selling pressure due to market volatility or broader economic concerns.
• Investors might be reassessing their positions in AMLX stock, leading to a temporary decline in its market value.

12.02.2025 - AMLX Stock was up 12.4%

• Amylyx Pharmaceuticals (AMLYX) experienced a strong bullish movement.
• The positive market sentiment and the overall bullish trend in the market could have contributed to the surge in AMLYX stock.
• There were no specific negative news related to AMLYX mentioned, indicating that the bullish movement might be more driven by market factors rather than company-specific news.
• Investors might be optimistic about the future prospects of Amylyx Pharmaceuticals, leading to increased buying interest and pushing the stock price higher.

13.07.2024 - AMLX Stock was up 5.0%

• AMLX stock experienced a strong bullish movement today.
• The bullish trend can be attributed to the encouraging data revealed on the effects of AMX0035 on cerebrospinal fluid biomarkers related to Alzheimer's disease pathology and neurodegeneration.
• The positive results from the Phase 2 trial, showing reduced tau levels and engagement of multiple pathological pathways, have likely boosted investor confidence in the potential of AMX0035 as a treatment for neurodegenerative diseases.
• The company's recent financial report for Q2 2024 may have also contributed to the positive sentiment surrounding AMLX stock, indicating a strong pipeline with assets targeting orphan indications and FDA Breakthrough Therapy Designation for one of their drugs.

09.07.2024 - AMLX Stock was up 5.1%

• The recent expansion of its late-stage pipeline with the acquisition of avexitide, a Phase 3-ready asset with FDA Breakthrough Therapy Designation, may have driven the bullish movement in AMLX stock.
• Despite a decline in revenue and net loss in the second quarter, investors appear optimistic about the company's pipeline expansion and progress in trials for avexitide and other assets.
• The market's positivity towards Amylyx Pharmaceuticals' new assets targeting orphan indications likely influenced the bullish movement in AMLX stock today.

08.07.2024 - AMLX Stock was down 5.2%

• Amylyx Pharmaceuticals (AMLYX) experienced a significant decline in revenue and a net loss in their Q2 2024 financial results.
• Despite obtaining Orphan Drug Designation for AMX0035 in Wolfram Syndrome from both the FDA and the European Commission, the market's reaction to the company's overall financial performance was negative.
• The acquisition of avexitide and the drug's Phase 3 readiness with FDA Breakthrough Therapy Designation could not counteract the bearish sentiment influenced by the financial results.
• Investors appear to have concerns about Amylyx Pharmaceuticals' capacity to convert its promising pipeline into sustainable revenue growth, which has contributed to the downward movement in AMLYX stock.

24.05.2025 - AMLX Stock was up 10.1%

• Amylyx Pharmaceuticals (NASDAQ: AMLX) experienced a strong bullish movement today.
• The upsurge in the stock's performance may be linked to a new analyst initiating a favorable outlook on the company.
• Analyst Marcus Cole from UBS commencing coverage on a positive note possibly bolstered investor confidence in AMLX.
• The optimistic analyst outlook likely played a role in driving the bullish momentum in AMLX's stock price during the day.